NCT06594094: An Open-label, Multidose Dose-escalation Study to Understand the Safety of CRISPR Gene-editing Therapy and Its Long-Lasting Effects in DMD Patients (MUSCLE)

Sponsor: HuidaGene Therapeutics Co., Ltd.. Phase: EARLY_PHASE1. Conditions: Duchenne Muscular Dystrophin (DMD)